Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results)

Journal of the American Society of Hypertension

Volumn 1, Issue 4, 2007, Pages 286-294

  Verma, Subodh ^a,e   Mamdani, Muhammad M ^c,e   Al Omran, Mohammed ^b   Melo, Magda ^c,e   Rouleau, Jean L ^d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

ACE inhibitors; angiotensin receptor blockers; myocardial infarction; population based study

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; NITRATE; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ARTICLE; ATHEROSCLEROSIS; CANADA; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG UTILIZATION; ENDARTERECTOMY; GERIATRIC PATIENT; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIMB AMPUTATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; RISK ASSESSMENT; RISK REDUCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 34547122508     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2007.05.003     Document Type: Article

References (32)

1. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 23 Suppl 1 (2005) S9-S17
2. Strauss M.H., and Hall A.S. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 114 (2006) 838-854
3. McMurray J., Solomon S., Pieper K., Reed S., Rouleau J., Velazquez E., et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 47 (2006) 726-733
4. Levy A.R., O'Brien B.J., Sellors C., Grootendorst P., and Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10 (2003) 67-71
5. Rubin D.B., and Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 52 (1996) 249-264
6. Rosenbaum P.R., and Rubin D.B. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79 (1984) 516-524
7. Austin P.C., Daly P.A., and Tu J.V. A multi-center study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 144 (2002) 290-296
8. Cox J.L., Melady M.P., Chen E., and Naylor C.D. Towards improved coding of acute myocardial infarction in hospital discharge abstracts: a pilot project. Can J Cardiol 13 (1997) 351-358
9. Schneeweiss S., Seeger J.D., Maclure M., Wang P.S., Avorn J., and Glynn R.J. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154 (2001) 854-864
10. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
12. Kober L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., et al., Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
13. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
14. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA Study). Lancet 362 (2003) 782-788
15. Dagenais G.R., Pogue J., Fox K., Simoons M.L., and Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006) 581-588
16. Teo K., Yusuf S., Sleight P., et al. Rationale, design, and baseline characteristics of two large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
17. Levy B.I. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease?. Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109 (2004) 8-13
18. Nakajima M., Hutchinson H.G., Fujinaga M., Hayashida W., Morishita R., Zhang L., et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 92 (1995) 10663-10667
19. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363 (2004) 2022-2031
20. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
21. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
22. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative Trial. Lancet 362 (2003) 772-776
23. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
24. Demers C., McMurray J.J., Swedberg K., Pfeffer M.A., Granger C.B., Olofsson B., et al., CHARM Investigators. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 294 (2005) 1794-1798
25. Epstein B.J., and Gums J.G. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann Pharmacother 39 (2005) 470-480
26. Strippoli G.F., Craig M., Deeks J.J., Schena F.P., and Craig J.C. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329 (2004) 828
27. Cheung B.M., Cheung G.T., Lauder I.J., Lau C.P., and Kumana C.R. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens 20 (2006) 37-43
28. McDonald M.A., Simpson S.H., Ezekowitz J.A., Gyenes G., and Tsuyuki R.T. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 331 (2005) 873
29. Volpe M., Mancia G., and Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 23 (2005) 2113-2118
30. Verdecchia P., Angeli F., Gattobigio R., and Reboldi G.P. Do angiotensin II receptor blockers increase the risk of myocardial infarction?. Eur Heart J 26 (2005) 2381-2386
31. Strauss M.H., Lonn E.M., and Verma S. Is the jury out?. Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Eur Heart J 26 (2005) 2351-2353
32. Bourgault C., Senecal M., Brisson M., Marentette M.A., and Gregoire J.P. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a Population-Based Study. J Hum Hypertens 19 (2005) 607-613